Role of splenic and bone marrow uptake at <sup>18</sup> F-FDG PET/CT for the assessment of large vessels vasculitis and the influence of glucocorticoids therapy on their values.
Details
Serval ID
serval:BIB_4CA55857260A
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Role of splenic and bone marrow uptake at <sup>18</sup> F-FDG PET/CT for the assessment of large vessels vasculitis and the influence of glucocorticoids therapy on their values.
Journal
Journal of medical imaging and radiation oncology
ISSN
1754-9485 (Electronic)
ISSN-L
1754-9477
Publication state
Published
Issued date
10/2023
Peer-reviewed
Oui
Volume
67
Number
7
Pages
717-725
Language
english
Notes
Publication types: Journal Article
Publication Status: ppublish
Publication Status: ppublish
Abstract
To assess the relationship between splenic and bone marrow (BM) uptake with the presence of large vessel vasculitis (LVV) at <sup>18</sup> F-FDG PET/CT and to evaluate the influence of glucocorticoid (GC) therapy on these uptakes.
One hundred and one subjects with LVV and <sup>18</sup> F-FDG PET/CT were included in the study. Clinical features, including blood samples and duration of GC therapy, were collected. Standardized uptake value body weight max (SUVmax) of the spleen, BM, liver and arterial walls were extracted; spleen/liver (SL) and BM/liver (BML) ratios were calculated. Chi-square and T-test were used to assess the relationship between PET/CT parameters and clinical features with the presence of LVV. Rank correlation was used to evaluate the correlation between PET/CT parameters and clinical parameters. Receiver operating curve (ROC) analysis was used to find the best parameter able to discriminate between positive and negative PET/CT. All analyses were performed considering the duration of GC therapy.
Significant correlation for PET/CT results with spleen uptake (P-value = 0.001), SL (P-value < 0.001) and BML (P-value = 0.005) were reported in patients with no more than 3 days of therapy; the correlation with SL was confirmed in the total cohort of patients. A value of 0.92 for SL had an AUC of 0.959, a sensitivity of 92.6% and a specificity of 96.6% (P-value < 0.001) in predicting PET/CT results.
Higher splenic and BM uptake in patients with positive PET/CT for LVV were reported. A long duration of GC therapy is able to reduce such uptakes.
One hundred and one subjects with LVV and <sup>18</sup> F-FDG PET/CT were included in the study. Clinical features, including blood samples and duration of GC therapy, were collected. Standardized uptake value body weight max (SUVmax) of the spleen, BM, liver and arterial walls were extracted; spleen/liver (SL) and BM/liver (BML) ratios were calculated. Chi-square and T-test were used to assess the relationship between PET/CT parameters and clinical features with the presence of LVV. Rank correlation was used to evaluate the correlation between PET/CT parameters and clinical parameters. Receiver operating curve (ROC) analysis was used to find the best parameter able to discriminate between positive and negative PET/CT. All analyses were performed considering the duration of GC therapy.
Significant correlation for PET/CT results with spleen uptake (P-value = 0.001), SL (P-value < 0.001) and BML (P-value = 0.005) were reported in patients with no more than 3 days of therapy; the correlation with SL was confirmed in the total cohort of patients. A value of 0.92 for SL had an AUC of 0.959, a sensitivity of 92.6% and a specificity of 96.6% (P-value < 0.001) in predicting PET/CT results.
Higher splenic and BM uptake in patients with positive PET/CT for LVV were reported. A long duration of GC therapy is able to reduce such uptakes.
Keywords
Humans, Positron Emission Tomography Computed Tomography/methods, Fluorodeoxyglucose F18, Glucocorticoids/therapeutic use, Radiopharmaceuticals, Bone Marrow/diagnostic imaging, Spleen/diagnostic imaging, Positron-Emission Tomography, Vasculitis, Retrospective Studies, 18F-FDG, positron emission tomography, spleen, vasculitis
Pubmed
Web of science
Open Access
Yes
Create date
24/07/2023 13:37
Last modification date
08/11/2023 7:09